CervoMed Inc. filings document a clinical-stage biotechnology issuer focused on neflamapimod and age-related brain disorders. Form 8-K reports include Regulation FD disclosures, press release exhibits, operating and financial results, and updates on clinical studies such as RewinD-LB in dementia with Lewy bodies, pharmacokinetic work, biomarker analyses, and ALS platform inclusion.
Proxy materials describe shareholder voting matters, board and governance practices, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also identifies CRVO common stock on the Nasdaq Capital Market and provides capital-structure, business-development, and financial-position disclosures relevant to CervoMed's drug-development model.
CervoMed Inc. (CRVO) Form 4 filing discloses an initial equity grant to newly elected non-employee director Dr. Marwan Sabbagh. On 06/23/2025 he received a stock option for 8,100 common shares at an exercise price of $6.52 under the 2025 Equity Incentive Plan. The option vests in equal 1/12-increments on the last day of each month from 06/30/2025 through 05/31/2026, contingent on continued board service, and expires on 06/23/2035. No common shares were purchased or sold, and total derivative holdings now stand at 8,100 options. The transaction is routine director compensation with negligible dilution and no immediate impact on CervoMed’s financial position.
CervoMed Inc. (CRVO) – Form 4 insider filing
On June 23, 2025 newly elected director Jeffrey V. Poulton received a non-qualified stock option for 8,100 common shares under the company’s 2025 Equity Incentive Plan. The option carries an exercise price of $6.52 and a ten-year term expiring June 23, 2035. Vesting occurs monthly in equal 1/12-increments beginning June 30, 2025 and completes after one year, contingent on continued board service.
No shares were bought or sold in the open market; the filing reflects an equity award customary for non-employee directors. Following the grant, Mr. Poulton beneficially owns 8,100 derivative securities and no change is reported for non-derivative holdings. The transaction was reported on June 25, 2025 and is categorized under Code “A” (grant) in Table II.
From an investor perspective, the filing is routine, modest in size and unlikely to materially impact the share count or near-term valuation, but it does strengthen director equity alignment.
CervoMed Director Jane H. Hollingsworth received a stock option grant following her election to the company's board of directors at the 2025 Annual Meeting of Stockholders. The transaction details include:
- Grant of options to purchase 8,100 shares of common stock
- Exercise price set at $6.52 per share
- Options granted on June 23, 2025 with expiration on June 23, 2035
- Vesting schedule: Monthly over one year in equal 1/12th increments
- Vesting begins June 30, 2025, subject to continued service
The stock options were granted under the company's 2025 Equity Incentive Plan in accordance with their non-employee director compensation policy. The Form 4 was filed by William R. Elder as attorney-in-fact for Hollingsworth.
CervoMed Director and 10% owner Sylvie Gregoire received a stock option grant following her election to the company's board of directors at the 2025 Annual Meeting of Stockholders. The transaction details include:
- Grant of options to purchase 8,100 shares of common stock
- Exercise price set at $6.52 per share
- Options granted on June 23, 2025 with expiration on June 23, 2035
- Vesting schedule: Monthly over one year in equal 1/12th increments starting June 30, 2025
- Grant made under the company's 2025 Equity Incentive Plan per non-employee director compensation policy
The options are subject to continued service through applicable vesting dates. The filing was signed by William R. Elder as attorney-in-fact for Gregoire on June 25, 2025.